Wushuang Medical Joins National High-Performance Medical Device Innovation Center's Arrhythmia Device R&D Base as Industrialization Partner
Singular Medical
Developer, Manufacturer, and Seller of Cardiac Rhythm Management Products
Medpark
Bone Graft Material Developer
Recently,Nanjing University National High-Performance Medical Device Innovation Center R&D Sub-Center and National High-Performance Medical Device Innovation Center Arrhythmia Device R&D BaseOfficially launched in Nanjing.Medpark Enterprise Singular Medical as the Industrialization BaseAttend the launch conference and join hands with Nanjing University, Drum Tower Hospital Affiliated to Nanjing University Medical School, and others to jointly initiate a new chapter in China's independent research and development of high-end cardiac rhythm management devices. Dr. Ping Lichuan, CEO of Singular Medical, serves as the deputy director of the Innovation Center and R&D Base.
Vice President of Nanjing University, Lu Yanqing; Chairman of the National Innovation Center for High-Performance Medical Devices, Liu Xin; Vice President of the Chinese Medical Doctor Association, Shi Shengfeng; Dean of the Affiliated Drum Tower Hospital of Nanjing University Medical School, Yu Chenggong; Chairman of the Arrhythmia Technology Branch of the Chinese Medical Equipment AssociationZhangShuOutAttended the launch conference and delivered a speech.
During the event, Ping Lichuan, CEO of Singular Medical, represented the National Innovation Center for High-Performance Medical Devices Arrhythmia Device R&D Base.Release of Five Core R&D Tasks:
▶Clinical Research:Build a CIED remote follow-up data system and develop digital therapies for specific conditions such as atrial fibrillation, stroke, and heart failure based on remote monitoring.
▶ Standard Establishment:Promote the formulation of key clinical standards such as MRI compatibility for implantable ECG products, targeted drug release from leads, and long-term reliability;
▶ProductR&D：Focus on developing intelligent medical devices such as dedicated chips for heart failure monitoring based on AI accelerators;
▶ Industrialization Research:Breakthrough in key materials and components such as domestically produced high-performance ceramic feedthroughs, titanium alloy housings, long-term implantable silicone, PEEK material, high-voltage batteries, and capacitors;
▶Frontier Exploration:Initiate preliminary research on next-generation technologies such as nanoscale ceramic-polymer composite coating conductors.
National Innovation Center for High-Performance Medical Devices
Arrhythmia Device R&D Base
As an important layout of the National Innovation Center for High-Performance Medical Devices in the field of arrhythmia diagnosis and treatment devices, this research base aims to build a "government-industry-academia-research-clinical application" collaborative innovation platform. Relying on the scientific research strength of Nanjing University and the clinical resources of Gulou Hospital, it will unite multidisciplinary teams and corporate forces to jointly tackle key technologies in arrhythmia diagnosis and treatment devices, enhancing China's independent research and development capabilities and international competitiveness in high-end cardiac rhythm management equipment.
Singular Medical is a hard-tech enterprise deeply engaged in the cardiac rhythm management (CRM) field, with a product layout covering the entire process of "prevention-diagnosis-treatment-management." The company owns over 140 Chinese patents and multiple U.S. patents, and two of its products have entered the special review process for innovative medical devices in China.
Ping Liuchuan stated, the participation in the construction of the National High-Performance Medical Device Innovation Center's arrhythmia device R&D base this time is a recognition of Singular Medical’s technical strength and innovation capabilities. The company will fully leverage this high-level platform, utilize collaborative innovation advantages, further expand investment in R&D and production, accelerate the transformation and application of new technologies and products, and comprehensively enhance the independent innovation capabilities of the enterprise.
In recent years, Medpark enterprises have deeply participated in the construction of high-level platforms and the formulation of industry standards, fully demonstrating Medpark's industrial cluster effect in the high-end medical device field. In the future, Medpark will continue to promote efficiency synergy and resource sharing among platforms, build a more dynamic industrial innovation ecosystem, and create a high-end medical device innovation hub in China.
